Avanafil

Research use only, not for human use.

A potent and highly selective PDE5 inhibitor (IC50=5.2 nM) for erectile dysfunction.

A potent and highly selective PDE5 inhibitor (IC50=5.2 nM) for erectile dysfunction; shows no significant effect on PDE1, PDE6 and PDE11.Sexual Dysfunction Approved(In Vitro):Avanafil (TA-1790) (0.01-1000 μM) enhances by 45% for electrical field stimulation (1-20 Hz)-induced relaxation responses in corpus cavernosum strips from the diabetic group.(In Vivo):Avanafil (TA-1790) (10 mg/kg; p.o.; daily, for 30 d; male rat) increases angiogenesis in bone tissue via the activation of NO, cGMP and PKG (NO/cGMP/PKG) signaling-pathway and significantly decreases dexamethasone-induced loss in BMD, bone atrophy, and oxidative stress.Avanafil (TA-1790) (10 μM; ICI; once, for 10 weeks) improves erectile responses in T2DM rats.

Avanafil (TA-1790) (0.01-1000 μM) enhances by 45% for electrical field stimulation (1-20 Hz)-induced relaxation responses in corpus cavernosum strips from the diabetic group.

Avanafil (TA-1790) (10 mg/kg; p.o.; daily, for 30 d; male rat) increases angiogenesis in bone tissue via the activation of NO, cGMP and PKG (NO/cGMP/PKG) signaling-pathway and significantly decreases dexamethasone-induced loss in BMD, bone atrophy, and oxidative stress.Avanafil (TA-1790) (10 μM; ICI; once, for 10 weeks) improves erectile responses in T2DM rats. Animal Model:Male rat model of glucocorticoid-induced osteoporosis (GIOP)Dosage:10 mg/kg Administration:Oral administration; daily, for 30 days Result:Decreased the level of eNOS, NO, PDE-5, PICP, MDA, CoQ10/CoQ10H and 8-OHdG/108dG. Increased the level of cGMP, PKG, Cortisol and CTCP.Animal Model:Male rat model of glucocorticoid-induced osteoporosis (GIOP)Dosage:10 mg/kg Administration:Oral administration; daily, for 30 days Result:Increased right femur trabecular bone thickness and epiphyseal bone width.Animal Model:Male T2DM Sprague Dawley rats Dosage:10 μM Administration:Intracavernous injection; once, for 10 weeks Result:Increased in ICP/MAP in response to nerve stimulation and increased total ICP values.

TA1790 | TA 1790 | TA-1790

Angiogenesis

PDE

PDE5

Endocrinology

Sexual Dysfunction

330784-47-9

483.9507

C23H26ClN7O3

>98% (HPLC)

10 mM in DMSO

O=C(C1=CN=C(N2[C@H](CO)CCC2)N=C1NCC3=CC=C(OC)C(Cl)=C3)NCC4=NC=CC=N4

5-Pyrimidinecarboxamide, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-

(-20℃)

With Ice Pack

≥ 2 years